Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 734-738    DOI: 10.12892/ejgo4597.201
Original Research Previous articles | Next articles
Differences in tumor behavior between serous and non-serous ovarian carcinoma, focus on distribution of stage, laterality and survival
S.-C. Liu1, Y.-C. Ou2, C.-H. Wu1, H.-C. Fu1, C.-C. Tsai1, C.-C. ChangChien1, H. Lin1, *()
1Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
2Department of Obstetrics and Gynecology, Chia-Yi Chang Gung Memorial Hospital, Chiayi County, Puzi City, Taiwan
Download:  PDF(410KB)  ( 226 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose: To determine the differences in tumor behavior between ovarian serous and non-serous carcinoma. Materials and Methods: We retrospectively collected the medical records of patients with epithelial ovarian cancer at our hospital from January 2010 to December 2015. We compared the clinicopathological behavior and survival between serous and non-serous carcinoma. Kaplan-Meier and Cox regression methods were used to analyze risk factors on survival. Results: A total of 268 patients were included, of whom 38.1% had serous carcinoma. The patients with serous carcinoma had significantly more advanced disease including extra-ovarian disease (89.2% vs. 34.3%), abdominal disease (69.6% vs. 22.9%), lymph node metastasis (39.2% vs. 14.4%), para-aortic lymph node involvement (17.7% vs. 5.4%), and FIGO Stage III/IV disease (78.4% vs. 28.3%). In addition, serous carcinoma tended to involve bilateral ovaries (65.7% vs. 22.3%). However, in FIGO Stage III/IV disease, serous carcinoma had a better overall survival than non-serous type (HR 0.469, 95% CI = 0.268-0.882, p = 0.008). Conclusions: Although serous carcinoma presented more metastasis, it appeared to have better survival when compared to non-serous type in advanced stage disease.

Key words:  Ovarian cancer      Tumor behavior      Serous carcinoma     
Published:  10 October 2019     
*Corresponding Author(s):  H. LIN     E-mail:  haolin@adm.cgmh.org.tw;haolin4237@yahoo.com.tw

Cite this article: 

S.-C. Liu, Y.-C. Ou, C.-H. Wu, H.-C. Fu, C.-C. Tsai, C.-C. ChangChien, H. Lin. Differences in tumor behavior between serous and non-serous ovarian carcinoma, focus on distribution of stage, laterality and survival. European Journal of Gynaecological Oncology, 2019, 40(5): 734-738.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4597.201     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/734

[1] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[2] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[3] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[4] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[5] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[6] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[7] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[8] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[9] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[10] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[11] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[12] C.J. Heesterbeek, A.M. Thijs, R.H.M. Hermans, D. Boll, G.-J. Creemers. Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 364-367.
[13] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[14] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[15] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
No Suggested Reading articles found!